Similarly, two clinical trials that administered ipilimumab to patients with metastatic melanoma or ovarian carcinoma that were previously vaccinated with autologous GM-CSF-secreting melanoma or ovarian cancer vaccines demonstrated extensive tumor necrosis or the reduction of cancer antigen-125 (CA-125) levels (50, 51). This evidence concerns the gene MUC16 and ovarian cancer.